Emory University’s Novavax NVAX Stock Holding History

Emory University’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-28	Closed	-$2K	–	96
2013 Q4	$2K	Buy	+28	New	+$1.98K	﹤0.01%	155

Other funds holding NVAX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Emory University's NVAX Position: Q1 2014 in Review

Emory University sold out of Novavax (NVAX) in Q1 2014, closing a stake of 28 shares — an estimated $2K sold.

Emory University first reported a position in NVAX in Q4 2013 and held it in 1 quarter. The position peaked at $2K in Q4 2013. 141 funds tracked by Wall St. Rank hold NVAX as of Q1 2014.

Emory University reported no remaining Novavax position as of Q1 2014 after selling out during the quarter.
Emory University sold 28 Novavax shares in Q1 2014, an estimated $2K.
Emory University first reported a position in Novavax in Q4 2013 and held it in 1 quarter.
Emory University's Novavax position peaked at $2K in Q4 2013.
141 funds tracked by Wall St. Rank held Novavax as of Q1 2014.

Based on Emory University's 13F filing for Q1 2014, filed 13 May 2014.